Heart failure market estimated to grow, driven by pipeline agents aimed at unmet needs
With pipeline approvals of varying mechanisms of action and an influx of newly diagnosed patients, the heart failure (HF) market is expected to grow at a 9.6% compound annual growth rate (CAGR) from $13.5bn in 2022 to $33.7bn in 2032 in the seven major …